Skip to main content

Table 3 Cost-utility analysis results from comparing paliperidone and risperidone long acting injections for chronic schizophrenia in Greece

From: Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece

Drug Total cost per patient* Total QALYs per patient Incremental cost per patient Incremental QALYs per patient Economic conclusion
PP-LAI €3,529 0.840 -€166 0.025 dominant
RIS-LAI €3,695 0.815    dominated
  1. LAI long acting injectable, PP paliperidone palmitate, RIS risperidone microspheres, QALY quality adjusted life years.
  2. *All costs are in 2011 Euros.